Patient-Derived Xenograft - PDX Models

Leverage the World’s Largest Collection of Highly-Characterized PDX Models

Patient-derived xenografts - PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population.

PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.

The Crown Bioscience PDX Model Collection:

Our HuPrime® PDX collection, with over 2500 well-characterized PDX models, supports translational preclinical oncology research into over thirty human cancer types – including rare indications and highly-specific molecular targets.

ALL AML Adrenal Bladder Brain Breast Cervical Cholangiocarcinoma Colorectal Esophageal

Gallbladder Gastric GIST Head and neck Kidney Liver Lung Lymphoma Melanoma Mesothelioma

Mixed mullerian Ovarian Pancreatic Prostate Sarcoma Testical Thyroid Uterine

Explore Our Collection

The HuKemia^® Blood Cancer PDX Collection

Evaluate blood cancer therapeutic candidates with validated, stable, truly patient representative leukemia models.

HuKemia is Crown Bioscience’s collection of validated blood cancer PDX models, fully annotated with patient information, diagnosis, and clinical treatments. These models have been fully quality controlled by our pathologists and are available with genotyping and phenotyping data.

Advantages of the HuKemia Blood Cancer PDX Collection

Crown Bioscience’s validated and well-characterized HuKemia models provide many advantages:

• Well-established models that have been used in over 100 preclinical studies, and are therefore a tried and tested approach for assessing preclinical efficacy
• Derived from patients treated with today's clinical therapeutics, including SOC targeted therapies and immunotherapeutics
• Present as stable disease that is transferable through passages, meaning results are highly reproducible across studies
• Overcome limitations with CDX models for systemic diseases. When utilizing CDX models, it can be highly challenging to detect the leukemic cells in the blood, limiting studies to only monitoring survival
• Can be repeatedly challenged to mimic clinical therapy and the emergence of resistance, which means that models of resistance can be created for testing next-generation drugs
• Optional ex vivo assays to leverage access to fresh tumor samples for all AML and ALL models, enabling the assessment of efficient combination and dosing regimens. An illustration of the HuKemia study design followed by ex vivo workflow is shown below

HuKemia Study Design

Explore Our Collection